Endocrine resistance in breast cancer patients is still a major clinical problem. A key role for Rac1-PAK1 signaling pathway in endocrine resistance is reported. Rac1 overactivation triggered a hormone-independent and tamoxifen resistant phenotype. 1A-116 Rac1 inhibitor restored tamoxifen resistance mechanisms in breast cancer cells.